DexCom Beats on Revenue, Matches Expectations on EPS
DexCom (NAS: DXCM) reported earnings May 2. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), DexCom beat slightly on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly and GAAP loss per share expanded.
Margins grew across the board.
DexCom notched revenue of $20.1 million. The 14 analysts polled by S&P Capital IQ foresaw net sales of $19.9 million on the same basis. GAAP reported sales were 42% higher than the prior-year quarter's $14.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.19. The 12 earnings estimates compiled by S&P Capital IQ forecast -$0.19 per share. GAAP EPS were -$0.21 for Q1 compared to -$0.19 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 46.7%, 1,060 basis points better than the prior-year quarter. Operating margin was -76.6%, 710 basis points better than the prior-year quarter. Net margin was -70.0%, 1,360 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $22.2 million. On the bottom line, the average EPS estimate is -$0.20.
Next year's average estimate for revenue is $94.4 million. The average EPS estimate is -$0.72.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 81 members rating the stock outperform and 98 members rating it underperform. Among 76 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 24 give DexCom a green thumbs-up, and 52 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on DexCom is outperform, with an average price target of $12.13.
Over the decades, small-cap stocks, like DexCom have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add DexCom to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.